本港新增12宗輸入確診個案
衛生署衛生防護中心公佈,截至12月30日凌晨零時,中心正調查12宗新增2019冠狀病毒病確診個案,全爲輸入個案;至今本港個案累計12,631宗。
新增個案涉及九男三女,年齡介乎1至61歲,當中有7宗涉及變異病毒株的感染,3宗的變異病毒株檢測結果待定,其餘2宗的病毒量不足以進行變異病毒株檢測。
過去十四天(12月16日至29日)累計報告122宗個案,1宗爲與輸入個案有流行病學關連的個案,其餘均爲輸入個案。
此外,根據衛生署公共衛生化驗服務處進行的全基因組測序分析結果,確認早前公佈的11宗確診個案帶有需要關注的變異病毒株Omicron,至今本港共錄得81宗涉及Omicron的個案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.